Skip to main content
SpringerLink
Log in

Dabigatran cost effective in AF but stroke and bleeding risk important

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

Reference

  • Wang CY, et al. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. PharmacoEconomics : 14 Sep 2020. Available from: URL: http://doi.org/10.1007/s40273-020-00960-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dabigatran cost effective in AF but stroke and bleeding risk important. Reactions Weekly 1823, 5 (2020). https://doi.org/10.1007/s40278-020-83633-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-83633-x

Search

Navigation